Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Blocking Granzyme K protein may protect organs from age-related damage

Monash University researchers have identified a protein that drives age-related damage in vital organs, opening a potential new avenue for treatments that could help people stay healthier as they get older.

12 Nov 2026

Inhaled living medicine reduces drug-resistant lung biofilms in the lungs of pigs

A "living medicine" has thinned biofilms of antibiotic-resistant Pseudomonas aeruginosa in the lungs of pigs, according to the findings of a study published today in the journal eBioMedicine.

12 Nov 2026

Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

Richmond Pharmacology, a specialist early-phase clinical research organization, has announced encouraging results from a first-in-human clinical trial evaluating CIDEBsiRNA, an investigational RNA interference (RNAi) therapy developed by Regeneron Pharmaceuticals, Inc.

12 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

UCLA study identifies lipid imbalance as pulmonary fibrosis trigger

A new UCLA Health study in mice has identified a new potential trigger for pulmonary fibrosis: lipid dysregulation (a fat imbalance) within alveolar macrophages.

9 Nov 2026

Monthly binge drinking increases advanced liver fibrosis risk in women

Women who consume four or more alcohol drinks on a single occasion once a month or more have increased odds of advanced liver fibrosis, a new study suggests.

9 Nov 2026

Qureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight's Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum's PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum's lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

From Qureight 9 Nov 2026

Study maps key regions driving inflammation in aging hearts

Scientists have long known that aging drives inflammation in the heart, but exactly how those changes are distributed throughout the organ has remained unclear.

6 Nov 2026

Novel method identifies active tRNAs during cellular protein synthesis

In a new study in Nature Methods, researchers at the Centre for Genomic Regulation (CRG) in Barcelona describe a technique that looks only at the tRNAs on ribosomes busy making proteins.

5 Nov 2026

Topadur’s Phase 2a trial of TOP-N53 for systemic sclerosis-associated digital ulcers advances to next dose levels

Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels.

5 Nov 2026

New nanovesicle therapy shows promise for treating alcohol-related liver disease

Alcohol-related liver disease (ALD) is characterized by hepatocellular injury, oxidative stress, inflammation, and extracellular matrix remodeling, yet effective therapies remain limited.

4 Nov 2026

Targeting EGFR signaling to reduce mucus overproduction in lung diseases

Airway mucus is part of innate lung defense, but when production overwhelms clearance, it obstructs airflow and worsens disease.

2 Nov 2026

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced the publication of a peer-reviewed Viewpoint in the European Respiratory Journal (ERJ).

From Qureight 2 Nov 2026

Myeloid immune cells play key roles in aortic health and disease

The aorta is often viewed primarily as the body's largest blood vessel-a durable conduit that delivers oxygen-rich blood from the heart to every organ.

30 Oct 2026

Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai

Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?"

30 Oct 2026

Mayo Clinic enters new medical era with precure research

Mayo Clinic researchers are uncovering the earliest shifts in disease biology - long before symptoms appear - revealing how disease takes root and opening new possibilities to identify, predict and potentially prevent disease before symptoms develop.

30 Oct 2026

Stem cell transplantation shows sustained benefits in severe systemic sclerosis

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation, adding important evidence on sustained positive clinical outcomes and long-term safety in patients treated for early severe systemic sclerosis.

29 Oct 2026

Major studies identify accurate non-invasive tests for liver disease

Two major international studies have delivered the strongest evidence to date on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, reducing reliance on liver biopsy.

29 Oct 2026

New iron contrast agent offers safer cardiac MRI scans

The Biomolecular Nanotechnology research group led by Ikerbasque research professor Aitziber L. Cortajarena from CIC biomaGUNE has developed a new iron-based contrast agent for magnetic resonance imaging that can be used for both diagnosis and treatment.

29 Oct 2026

DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.

28 Oct 2026

Fibrosis News and Research

Further Reading

Blocking Granzyme K protein may protect organs from age-related damage

Inhaled living medicine reduces drug-resistant lung biofilms in the lungs of pigs

Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

UCLA study identifies lipid imbalance as pulmonary fibrosis trigger

Monthly binge drinking increases advanced liver fibrosis risk in women

Qureight's fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Study maps key regions driving inflammation in aging hearts

Novel method identifies active tRNAs during cellular protein synthesis

Topadur’s Phase 2a trial of TOP-N53 for systemic sclerosis-associated digital ulcers advances to next dose levels

New nanovesicle therapy shows promise for treating alcohol-related liver disease

Targeting EGFR signaling to reduce mucus overproduction in lung diseases

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Myeloid immune cells play key roles in aortic health and disease

Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai

Mayo Clinic enters new medical era with precure research

Stem cell transplantation shows sustained benefits in severe systemic sclerosis

Major studies identify accurate non-invasive tests for liver disease

New iron contrast agent offers safer cardiac MRI scans

DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News